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Glioblastoma multiforme (GBM) is the most common and malignant primary intracranial tumor, and has a median
survival of only 10 to 14 months with only 3 to 5% of patients surviving more than three years. Recurrence (RGBM)
is nearly universal, and further decreases the median survival to only five to seven months with optimal therapy.
Tumor-treating fields (TTField) therapy is a novel treatment technique that has recently received CE and FDA
approval for the treatment of RGBM, and is based on the principle that low intensity, intermediate frequency
electric fields (100 to 300 kHz) may induce apoptosis in specific cell types. Our center was the first to apply TTField
treatment to histologically proven GBM in a small pilot study of 20 individuals in 2004 and 2005, and four of those
original 20 patients are still alive today. We report two cases of GBM and two cases of RGBM treated by TTField
therapy, all in good health and no longer receiving any treatment more than seven years after initiating TTField
therapy, with no clinical or radiological evidence of recurrence.
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Glioblastoma multiforme (GBM) is the most common
and malignant primary intracranial tumor, representing
as much as 30% of primary brain tumors with increasing
incidence in some geographic regions [1]. Its incidence
has been shown to increase with age [2]. Despite the
introduction of aggressive treatment with temozolomide,
the median survival time of adult patients remains ap-
proximately 10 months and as high as 14 months in
patients receiving combined treatment with radiotherapy
[3]. Only 3 to 5% of patients survive more than three
years [4], and sporadic reports of survival exceeding five
years are rare [5]. The exact clinical and molecular fac-
tors that contribute to such long-term survival are still
unknown; however, younger age and a high Karnofsky
performance scale (KPS) are considered prognostically
favorable factors [4]. Recently, MGMT gene promoter* Correspondence: josef.vymazal@homolka.cz
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reproduction in any medium, provided the ormethylation and IDH1 mutation have been shown to
correlate with longer survival as well [6]. Recurrence of
GBM is nearly universal, and patients with recurrent
glioblastoma multiforme (RGBM) fare even worse, with
a median survival of only five to seven months with opti-
mal therapy [7].
Tumor-treating fields (TTField) therapy is a novel
treatment technique with the potential to treat various
forms of cancer. TTField therapy is based on the
principle that low intensity, intermediate frequency elec-
tric fields (100 to 300 kHz) have an anti-mitotic effect
which acts during late metaphase and anaphase, with
specific frequencies affecting specific cell types [8]. The
applied fields disrupt mitotic spindle microtubule assem-
bly and the segregation of intracellular organelles during
cell division, leading to apoptosis [9]. TTField therapy
has been tested in patients with advanced non-small cell
lung cancer [10] and has recently received CE and FDA
approval for the treatment of RGBM based on the
results of a phase III clinical trial [11].
Our center was the first in the world to apply TTField
treatment to histologically proven GBM patients in aLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Participant baseline characteristics
Patient no. Group Date of birth Date of inclusion Age at inclusion Gender Weight (kg) KPS (%) Tumor location
1 RGBM 07/1950 05/2004 53.8 Male 70 100 R. Temporoparietal
2 RGBM 08/1945 05/2004 58.8 Male 83 100 R. Temporal
3* RGBM 06/1952 08/2004 52.2 Female 65 70 R. Parietal
4* RGBM 08/1961 08/2004 43.1 Male 85 100 L. Frontoparietal
5 RGBM 05/1937 10/2004 67.5 Male 83 80 R. Temporoparietal
6 RGBM 05/1953 01/2005 51.7 Male 103 70 R. Parietooccipital
7 RGBM 04/1950 01/2005 54.8 Male 85 90 R. Frontotemporal
8 RGBM 06/1966 06/2005 39 Male 72 100 R. Temporoparietal
9 RGBM 06/1977 08/2005 28 Female 70 90 L. Temporoparietooccipital
10 RGBM 08/1948 09/2005 57 Female 68 70 L. Temporal
11 GBM 11/1968 01/2005 36 Male 77 100 L. Frontal
12 GBM 04/1935 05/2005 70 Male 79 90 R. Temporal
13* GBM 12/1973 10/2005 32 Male 85 100 R. Frontal
14 GBM 03/1948 01/2006 58 Male 81 100 R. Temporal
15 GBM 10/1963 01/2006 42 Male 96 90 R. Temporal
16 GBM 03/1961 01/2006 45 Female 50 100 R. Frontal
17* GBM 08/1973 04/2006 33 Female 65 90 R. Frontal
18 GBM 07/1951 10/2006 55 Male 80 100 L. Occipital
19 GBM 05/1941 09/2006 65 Male 85 80 L. Frontotemporal
20 GBM 05/1951 01/2007 56 Male 82 90 R. Temporal
* case in present report.
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(Table 1). The inclusion criteria of the study included a
KPS ≥70% and age ≥18 years, and the patients were
divided into two groups. The first group consisted of 10
patients diagnosed with RGBM after failing temozolo-
mide treatment that were treated with TTField therapy
alone [9]. The second group consisted of 10 newly diag-
nosed GBM patients at least four weeks post radiation
therapy (with adjuvant temozolomide) [12] that received
TTField therapy combined with maintenance temozolo-
mide. The treatment duration in individual patients var-
ied between one and one and a half years, and all
histological samples were independently examined in
two laboratories in two countries. We report two cases
of GBM and two cases of RGBM treated by TTField
therapy, all in good health and no longer receiving any
treatment more than seven years after initiating TTField
treatment, with no clinical or radiological evidence of
recurrence.
Baseline characteristics of all 20 participants in the ori-
ginal pilot study. Dates are presented as month/year for
simplicity, age calculations were performed on exact
dates.
GBM, glioblastoma multiforme (newly diagnosed);
KPS, Karnofsky performance scale; L., left; No., number;
R., right; RGBM, recurrent glioblastoma multiforme.Case presentation
Case 1
A 52-year-old woman with a history of epileptic seizures
and left-sided hemiparesis was diagnosed with an intra-
axial brain tumor, suspected to be a high-grade glioma
based on the magnetic resonance imaging (MRI) find-
ings (Figure 1a). The tumor was resected with the help
of functional blood oxygen level dependence (BOLD-
fMRI) neuronavigation in April 2004. Gross total resec-
tion was performed and pathological analysis revealed
clear evidence of glioblastoma. Standard radiotherapy
(60 Gy) and chemotherapy with temozolomide followed.
After radiotherapy and chemotherapy, a follow-up MRI
in July 2004 showed two enhancing lesions that were
highly suspected to be tumor recurrence (Figure 1b).
TTField therapy was initiated in August 2004 as mono-
therapy. In September 2004, one month after starting
TTField therapy, one of the enhancing lesions increased
in size (Figure 1c); however, treatment with TTField
therapy was continued since the progression was asymp-
tomatic. By February 2005, both enhancing lesions had
disappeared (Figure 1d) and are no longer detectable
(Figure 1e). TTField treatment was discontinued after
one year in August 2005, with no treatment adminis-
tered after that time. The last MR examination from
August 2011 shows no evidence of enhancing tumor.
Figure 1 Serial MR imaging in Case 1. T1-weighted image after application of contrast agent. a) April 2004, before surgery. GBM located in the
right central region. b) July 2004, post-operative radiotherapy and chemotherapy. Two enhancing lesions present. c) September 2004, one month
after the start of TTField therapy. The dorsal enhancing lesion increased in size, highly suspicious of tumor recurrence. d) June 2005, TTField
treatment. No enhancing lesion present. e) August 2011. No enhancing lesion present. GBM, glioblastoma multiforme; MR, magnetic resonance;
TTField, tumor-treating fields.
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and otherwise feels completely healthy with no subject-
ive complaints and a KPS of 90.
Case 2
A 41-year-old male presented with pronunciation diffi-
culties in December 2003. Neurological examination
revealed slight right-sided hemiparesis, and MRI
revealed an intra-axial tumor suspected to be high-grade
glioma (Figure 2a). Surgery was delayed due to intercur-
rent infection (influenza) until March 2004, and the
tumor was then partially resected. Pathological analysis
revealed histological characteristics of glioblastoma.
Standard radiotherapy (60 Gy) and chemotherapy with
temozolomide followed. A follow-up examination in Au-
gust 2004 showed an enhancing lesion suspected to be a
recurrent tumor (Figure 2b). TTField therapy was
initiated in August 2004. By March 2005 the enhancing
tumor had progressed and become cystic (Figure 2c).
Again, treatment with TTField therapy was continued
due to the asymptomatic nature of this progression. By
October 2005 the tumor had regressed (Figure 2d) while
the patient was still receiving TTField therapy. TTField
therapy was discontinued in February 2006. A discrete,
enhancing lesion is still present (last MRI in November
2011, Figure 2e). This small, enhancing lesion was exam-
ined with MR spectroscopy (Figure 2f ) and showed
noise-signal only, while the spectra in neighboring voxels
were practically normal (Figure 2g). Positron emission
tomography (PET) did not reveal any tumor-like pat-
terns. The patient is in good health, has minor difficul-
ties with speech, and is completely independent, with a
KPS of 90 to 100.
Case 3
A 31-year-old male presented with an epileptic seizure
in January 2005. MRI examination revealed a tumor in
the right frontal lobe that was suspected to be a high
grade glioma (Figure 3a). The tumor was totally resectedmacroscopically (gross total resection) and showed clear
histopathological characteristics of glioblastoma (World
Health Organization (WHO) grade IV). Standard radio-
therapy (60 Gy) and chemotherapy with temozolomide
followed. TTField treatment was started in October
2005 concomitant to maintenance temozolomide and
both treatments were discontinued in October 2006.
Since that time, no tumor recurrence has been detected
(Figure 3b). The patient is in good health, off all treat-
ment and with a KPS of 100.
Case 4
A 33-year-old female underwent MRI of the brain fol-
lowing an epileptic seizure in November 2005. A tenta-
tive diagnosis of high-grade glioma was made based on
MRI findings (Figure 4a). The tumor was completely
resected macroscopically (gross total resection) in Febru-
ary 2006 and showed clear histopathological characteris-
tics of glioblastoma (WHO grade IV). Standard
radiotherapy (60 Gy) and chemotherapy with temozolo-
mide followed. No recurrence was noted on follow-up
MRI in February 2007 (Figure 4b). TTField treatment
was started in April 2006 concomitant to maintenance
temozolomide and both treatments were discontinued in
April 2007. No tumor recurrence has been detected on a
number of follow-up MRI examinations (Figure 4c), the
last of which was performed in September 2011. MR
spectroscopy in a small volume of tissue with corre-
sponding increased signal intensity on Fluid Attenuated
Inversion Recovery (FLAIR) images did not show a
tumor-like pattern (Figure 4d). Currently the patient is
off all treatment, in good health, with a KPS of 100.
Discussion
Despite multi-modal treatment, the prognosis of GBM
remains poor. Recurrence is likely inevitable provided
the patient survives long enough, and further reduces
the median survival to only five to seven months [4,7].
There have been documented cases of GBM patients
Figure 3 Serial MR imaging in case 3. T1-weighted image after application of contrast agent. a) January 2005 before surgery. GBM located in
the right frontal region. b) December 2011. No tumor recurrence detected. GBM, glioblastoma multiforme; MR, magnetic resonance.
Figure 2 Serial MR imaging in Case 2. T1-weighted image after application of contrast agent. a) January 2004, before surgery. GBM located in
the left frontal region. b) August 2004, post-operative radiotherapy and chemotherapy. Start of TTField treatment. An enhancing lesion suspected
to be recurrent or residual tumor. c) March 2005, TTF treatment. The enhancing lesion became partly cystic. d) June 2005, regression of the cystic
part. A subtle enhancing lesion still present. e) November 2011. A subtle enhancing lesion without progression. f) Proton MR spectroscopy of the
enhancing lesion with dominant noise signal, suggesting gliosis rather than tumor. g) Neighboring spectrum is practically normal, demonstrating
that MR spectroscopy provided reliable data from the selected slice. GBM, Glioblastoma multiforme; MR, magnetic resonance; TTField,
tumor-treating fields.
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Figure 4 Serial MR imaging in case 4. T1-weighted image after application of contrast agent. a) November 2005, before surgery. GBM located
in the right frontal region. b) May 2006, a small, extra-axial enhancing lesion. c) September 2011, no change of the enhancing lesion. d) FLAIR
and MR spectroscopy images, September 2011. The small volume of increased signal intensity on FLAIR images did not show a tumor-like
pattern on MR spectroscopy. FLAIR, Fluid Attenuated Inversion Recovery; GBM, glioblastoma multiforme; MR, magnetic resonance.
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vival (LTS), representing approximately three to five per-
cent of GBM patients [4]. Survival of GBM patients
longer than five years, however, is exceptional, represent-
ing as few as 0.5% of patients [5].
Twenty percent of the participants in our pilot study
(4 out of 20) have survived until the time of this report,
roughly seven years (Figure 5). These individuals con-
tinue to undergo regular neurological and radiological
examinations, and do not show any signs of recurrence.
The data from standard MR imaging are further sup-
ported by MR spectroscopy that does not show anyFigure 5 Kaplan-Meier survival curves. Kaplan-Meier survival
curves for all 20 participants in the original pilot study, both as a
single group and divided into recurrent and newly diagnosed
glioblastoma multiforme. Two patients were lost to follow-up in the
newly diagnosed group and are represented by censor marks.tumor-like patterns in regions with corresponding ab-
normal signal intensity.
Younger age and a higher KPS have been proposed as
prognostically favorable parameters for longer survival
[4]. The mean age of our LTS-RGBM patients (Cases 1
and 2) was 47.5 years compared to 51.5 years for the rest
of the RGBM group [9]. This difference is not striking.
Although we cannot completely exclude pseudo-
progression or radiation necrosis in these patients diag-
nosed without histological verification of the recurrent
lesion, their continued survival is still remarkable. In the
group of newly diagnosed GBM, the mean age of LTS-
GBM patients (Cases 3 and 4) was 32 years compared to
51 years for the rest of the group. This was likely a con-
tributing factor to their long term survival; however, this
does not explain seven years of disease-free survival. All
of the patients in the trial had a KPS ≥70 and the me-
dian KPS was 80.
TTField therapy has been shown to effectively inhibit
glioma cell replication in vitro and in vivo [8,9]. The
published results of the pilot trial using TTField therapy
in GBM patients were extremely promising and served
as the basis for a phase III clinical trial comparing
TTField therapy to the best available active chemother-
apy in patients with RGBM [11]. The phase III trial
showed that patients with RGBM had comparable over-
all survival to those receiving chemotherapy without the
side effects of chemotherapy and with a better quality of
life. In the present study, no serious, probable,
treatment-related adverse events occurred, with only
contact dermatitis treated by topical corticosteroid docu-
mented in 17 of 20 patients. In the phase III trial, 8% of
TTField therapy patients survived for longer than three
years [11]. The reasons for the smaller number of long
term survival patients in the phase III trial compared to
the pilot trial is likely related to the younger age of the
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at their first recurrence after temozolomide (versus sec-
ond to third recurrence in the phase III trial) and, most
importantly, continued TTField therapy for many
months, despite initial growth of the contrast enhancing
lesion while on therapy. Thus, we suggest that in order
to increase the probability of response to TTField ther-
apy and subsequent long term survival, TTField treat-
ment should be continued even in the face of initial
radiologic tumor growth.
Conclusions
In the present paper we report two cases of GBM and
two cases of RGBM treated by TTField therapy, all in
good health and no longer receiving any treatment more
than seven years after initiating TTField therapy, with
no clinical or radiological evidence of recurrence. Our
results indicate that TTField treatment may be remark-
ably successful in a subgroup of GBM/RGBM patients,
and further investigation is needed to identify any
unique characteristics of this patient group.
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